Skip to content
PubMed This is a summary of 9 peer-reviewed journal articles Updated
Antiphospholipid Syndrome

The Science of APS: Why the 'Two-Hit' Model Matters

At a Glance

The APS two-hit model explains that genetic immune-system susceptibility may create the first hit, while an event such as infection, surgery, pregnancy, or hormone exposure provides the second. Together they can activate clotting, although clots may occur without a clear trigger.

While many conditions are caused by a single “broken” gene, Antiphospholipid Syndrome (APS) is far more complex. It is best understood through the two-hit model or hypothesis. This theory offers a framework to explain why one person might have APS antibodies for decades and feel fine, while another person with the same antibodies experiences a life-altering blood clot. To understand this, we have to look at how your internal biology interacts with the world around you.

Hit 1: The Genetic Foundation

The “first hit” is your genetic blueprint. You are born with a susceptibility to APS, but genes alone do not cause the disease [1]. Scientists have identified several markers that act like “volume knobs,” turning up the sensitivity of your immune system.

  • HLA Alleles: The most common genetic markers associated with APS are found in the HLA region, which helps your immune system distinguish your own cells from invaders. Markers like HLA-DR4 and HLA-DRw53 are frequently found in people with APS [2][3].
  • Non-HLA Genes: Other genes, such as STAT4 and C1D, have also been linked to the condition [1]. These genes don’t “give” you APS; they simply make it more likely that your immune system will produce the specific antibodies that characterize the disease [2]. Note: These are research associations, not a validated genetic test that can predict your outcome, and routine genetic testing is not currently part of APS care.

The Bad Actor: Beta-2-Glycoprotein I

The primary “bad actor” in APS is often a group of antibodies that mistakenly target a protein called Beta-2-glycoprotein I (β2GPI) [4].

Normally, β2GPI circulates in your blood without causing trouble. However, in people with the genetic “first hit,” the immune system sees this protein as an enemy. When these antibodies bind to β2GPI, they latch onto the endothelium (the delicate inner lining of your blood vessels) [5]. This binding sends a signal to your body that the blood vessel is damaged, even when it isn’t, setting the stage for a clot to form [4].

Hit 2: The Environmental Trigger

If the genetic markers are the “dry brush” in a forest, the “second hit” is the match. This trigger is an environmental event that puts stress on the body, pushing the already-sensitive immune system into an overactive state [4][6].

Common “second hits” include:

  • Infections: Even a common virus or bacterial infection can activate the immune response [7].
  • Surgery or Trauma: Physical injury or the stress of a surgical procedure can trigger the clotting process [8].
  • Pregnancy: The physiological changes of pregnancy and the postpartum period are significant stressors that can act as a trigger [9].
  • Hormonal Changes: Starting estrogen-based birth control or hormone replacement therapy can sometimes serve as a second hit [6].

The Chain Reaction: Complement and Neutrophils

Once the second hit occurs, a rapid chain reaction begins. The antibodies don’t just sit on the vessel wall; they activate the complement system, a part of your immune system that “complements” the work of antibodies to clear out threats [9][5].

In APS, the complement system becomes hyper-activated, which in turn recruits neutrophils (a type of white blood cell). These neutrophils can release “nets” of DNA and proteins called Neutrophil Extracellular Traps (NETs). While NETs are meant to trap bacteria, in APS, they can actually trap blood cells and proteins, leading directly to the formation of a clot [4][9].

Understanding this two-hit model is empowering, but it is important to remember it is an incomplete model. Clots can sometimes occur without a clear trigger, and experiencing a clot is never a sign that you “failed” to manage your lifestyle.

Common questions in this guide

What does the two-hit model mean in antiphospholipid syndrome?
The model proposes that a person may first have an inherited tendency to make APS antibodies, while an event such as an infection, surgery, pregnancy, or hormone exposure provides a second hit that activates clotting. Genes or antibodies alone do not always lead to a clot, and clots can occur without an obvious trigger.
Does a family history of APS mean I will develop it?
No. Certain immune-system gene markers may increase susceptibility, but APS is not caused by one known inherited gene, and these research associations cannot predict an individual’s outcome. A family history is worth discussing with your clinician, but routine genetic testing is not currently part of APS care.
What events can trigger a blood clot in APS?
Potential second hits include infections, surgery or physical trauma, pregnancy or the postpartum period, and estrogen-containing birth control or hormone replacement therapy. Ask your clinician how to plan for situations such as long flights, surgery, infections, or hormone treatment because your risk depends on your medical history and antibody profile.
How do APS antibodies cause blood clots?
Some APS antibodies attach to beta-2-glycoprotein I, a blood protein, and the inner lining of blood vessels. This can activate a part of the immune system called complement and recruit infection-fighting white blood cells, which release webs that can trap blood cells and clotting proteins. These changes make a clot more likely to form.
Can genetic testing predict whether I will have an APS clot?
Researchers have linked APS with immune-system gene markers such as HLA-DR4, HLA-DRw53, STAT4, and C1D, but these are research associations rather than tests that predict whether one person will develop a clot. Routine genetic testing is not currently part of APS care. Ask your clinician whether any testing is appropriate for your family history.
What should I discuss before surgery if I have APS?
Ask your care team for a plan to manage any blood thinner before, during, and after surgery and to reduce infection and clotting risks. Do not stop or change an anticoagulant on your own because the timing must be individualized.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do I have the 'triple-positive' antibody profile, and what does that mean for my risk of a second hit?
  2. 2.Given my family history, which specific genetic markers (like HLA-DR4) were found if I was tested, and how do they influence my care?
  3. 3.What specific 'second hit' scenarios should I be most careful about—for example, long flights, certain surgeries, or specific infections?
  4. 4.How exactly do the antibodies in my blood interact with my blood vessel walls (endothelium)?
  5. 5.If I need surgery in the future, what is our 'hit prevention' plan for managing my blood thinners and infection risk?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (9)
  1. 1

    Genetics of Antiphospholipid Syndrome.

    Ortiz-Fernández L, Sawalha AH

    Current rheumatology reports 2019; (21(12)):65 doi:10.1007/s11926-019-0869-y.

    PMID: 31807905
  2. 2

    Genetic aspects of the antiphospholipid syndrome: An update.

    Sebastiani GD, Iuliano A, Cantarini L, Galeazzi M

    Autoimmunity reviews 2016; (15(5)):433-9.

    PMID: 26804759
  3. 3

    Distribution of HLA-DRB1 Alleles in Patients With Antiphospholipid Syndrome and Their Association With Antiphospholipid Antibodies Presence and Damage Indexes.

    Haladyj E, Stypinska B, Matusiewicz A, et al.

    Journal of immunology research 2025; (2025()):2827348 doi:10.1155/jimr/2827348.

    PMID: 40165867
  4. 4

    Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome.

    Yang L, Guo R, Liu H, et al.

    Frontiers in immunology 2025; (16()):1527554 doi:10.3389/fimmu.2025.1527554.

    PMID: 40181965
  5. 5

    An Update on Antiphospholipid Syndrome.

    Xourgia E, Tektonidou MG

    Current rheumatology reports 2022; (23(12)):84 doi:10.1007/s11926-021-01051-5.

    PMID: 34985625
  6. 6

    Catastrophic Antiphospholipid Syndrome: A Review of Current Evidence and Future Management Practices.

    Okunlola AO, Ajao TO, Sabi M, et al.

    Cureus 2024; (16(9)):e69730 doi:10.7759/cureus.69730.

    PMID: 39429267
  7. 7

    McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome.

    Legault K, Schunemann H, Hillis C, et al.

    Journal of thrombosis and haemostasis : JTH 2018; (16(8)):1656-1664 doi:10.1111/jth.14192.

    PMID: 29978552
  8. 8

    [2016 review on catastrophic antiphospholipid syndrome].

    Costedoat-Chalumeau N, Coutte L, Le Guern V, et al.

    Presse medicale (Paris, France : 1983) 2016; (45(12 Pt 1)):1084-1092 doi:10.1016/j.lpm.2016.07.023.

    PMID: 27617783
  9. 9

    Antiphospholipid Antibody Syndrome and Infertility.

    Rodrigues VO, Soligo AGES, Pannain GD

    Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 2019; (41(10)):621-627 doi:10.1055/s-0039-1697982.

    PMID: 31658490

This page explains the two-hit model of antiphospholipid syndrome for informational purposes only and does not replace medical advice. Discuss your personal clotting risks, genetic questions, and any blood-thinner plan with your healthcare team.

Get notified when new evidence is published on familial antiphospholipid syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.